

Press release – For immediate release January 14, 2019 – 5:45pm CET

Yearly Median Technologies liquidity contract statement contracted with AUREL BGC Company

Sophia Antipolis, France – Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account as of December 31, 2018:

- € 93,902.83
- 49,634 shares

For information, as of June 30, 2018, the following resources were listed in the liquidity account:

- € 131,204.47
- 31,040 shares



About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors

and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). For more information: www.mediantechnologies.com

Contacts

Median Technologies	Press - ALIZE RP	Investors - ACTIFIN
Emmanuelle Leygues	Caroline Carmagnol /Wendy Rigal	Ghislaine Gasparetto
Senior Director, Corporate Communications	+ 33 1 44 54 36 66	+33 1 56 88 11 11
+33 6 10 93 58 88	median@alizerp.com	ggasparetto@actifin.fr
emmanuelle.leygues@mediantechnologies.com		